Literature DB >> 2295111

Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

S C Mann1, P A Andrews, S B Howell.   

Abstract

We examined the short-term accumulation of cisplatin (DDP) in sensitive 2008 human ovarian carcinoma cells and in a 2- to 3-fold DDP-resistant and accumulation-deficient variant. During the 1st min of exposure to 500 microM DDP, sensitive cells accumulated platinum at a rate of 187 +/- 63 pmol/mg protein per min, whereas resistant cells accumulated platinum at 123 +/- 85 pmol/mg protein per min, a rate that was 66% that of sensitive cells. From 2-10 min of exposure, sensitive and resistant cells accumulated the drug at rates of 51.4 +/- 21.5 and 34.0 +/- 9.70 pmol/mg protein per min, respectively. In resistant cells, this rate again represented 66% that of sensitive cells. For each cell line, the DDP accumulation was 3.6 times faster during the 1st min than it was over 2-10 min. Initial DDP accumulation was linear with drug concentration in each cell line. Efflux measurements were made over a 50-min period after a 10-min load in 500 microM DDP. The loss of platinum was biphasic in each cell line, with an initial, rapidly effluxing component being lost within 10 min in each cell line. The rate constant for loss of platinum from this rapidly effluxing pool, measured after a 10-min loading period in 500 microM DDP, was 0.67 +/- 0.09 s-1 in sensitive cells and 1.03 +/- 0.15 s-1 (a 53% increase) in resistant cells. Between 5 and 50 min of an accumulation time course in 500 microM DDP, the size of the rapidly effluxing platinum pool remained relatively constant in each cell line, with the major contribution to the increase in total platinum over time coming from growth of the slowly effluxing platinum pool. We conclude that diminished retention of platinum in the rapidly effluxing pool of resistant cells is a major determinant of decreased DDP accumulation in these cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295111     DOI: 10.1007/bf00684878

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors.

Authors:  P J DiSaia; J G Sinkovics; F N Rutledge; J P Smith
Journal:  Am J Obstet Gynecol       Date:  1972-12-01       Impact factor: 8.661

2.  Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents.

Authors:  G R Gale; C R Morris; L M Atkins; A B Smith
Journal:  Cancer Res       Date:  1973-04       Impact factor: 12.701

3.  Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell.

Authors:  I D Goldman; N S Lichtenstein; V T Oliverio
Journal:  J Biol Chem       Date:  1968-10-10       Impact factor: 5.157

4.  Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).

Authors:  B A Teicher; S A Holden; M J Kelley; T C Shea; C A Cucchi; A Rosowsky; W D Henner; E Frei
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

5.  Uptake of platinum compounds in human tumors. In vitro study.

Authors:  B Hecquet; A Leroy; J L Lefebvre; J P Peyrat; L Adenis
Journal:  Bull Cancer       Date:  1986       Impact factor: 1.276

6.  Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion.

Authors:  P A Andrews; M P Murphy; S B Howell
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

7.  Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.

Authors:  W R Waud
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

8.  Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug.

Authors:  K E Wallner; M W DeGregorio; G C Li
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

9.  Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).

Authors:  S Shionoya; Y Lu; K J Scanlon
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

10.  The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro.

Authors:  H Eichholtz-Wirth; B Hietel
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

View more
  19 in total

Review 1.  Role of copper transporters in platinum resistance.

Authors:  Deepak Kilari; Elizabeth Guancial; Eric S Kim
Journal:  World J Clin Oncol       Date:  2016-02-10

2.  Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin.

Authors:  Elene Pereira-Maia; Arlette Garnier-Suillerot
Journal:  J Biol Inorg Chem       Date:  2003-05-17       Impact factor: 3.358

3.  Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.

Authors:  Brian G Blair; Christopher A Larson; Roohangiz Safaei; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

4.  Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.

Authors:  S Y Sharp; P Mistry; M R Valenti; A P Bryant; L R Kelland
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells.

Authors:  P Naredi; D D Heath; R E Enns; S B Howell
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

6.  Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression.

Authors:  Alessio Ligabue; Gaetano Marverti; Ursula Liebl; Hannu Myllykallio
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

Review 7.  Cellular accumulation of the anticancer agent cisplatin: a review.

Authors:  D P Gately; S B Howell
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

8.  Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.

Authors:  Shengqing Gu; Stephanie Lheureux; Azin Sayad; Paulina Cybulska; Liat Hogen; Iryna Vyarvelska; Dongsheng Tu; Wendy R Parulekar; Matthew Nankivell; Sean Kehoe; Dennis S Chi; Douglas A Levine; Marcus Q Bernardini; Barry Rosen; Amit Oza; Myles Brown; Benjamin G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-22       Impact factor: 11.205

9.  Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line.

Authors:  S Isonishi; D K Hom; A Eastman; S B Howell
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

10.  Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.

Authors:  S Y Loh; P Mistry; L R Kelland; G Abel; K R Harrap
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.